Fostamatinib, an inhibitor of spleen tyrosine kinase (Syk), has shown therapeutic benefit in patients with IgA nephropathy and ANCA-associated vasculitis, partly by limiting macrophage infiltration. Here, SYK is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.